8-K: Nevro Announces Preliminary Q4 and Full-Year 2024 Revenue: Exceeds Guidance but Shows Year-Over-Year Decline

Nevro Corp. reports preliminary Q4 and full-year 2024 revenue, exceeding prior guidance for the year but showing a year-over-year decrease.

Summary

• Nevro Corp. expects fourth-quarter 2024 worldwide revenue to be approximately $105 million to $106 million, a decrease of 9% to 10% compared to Q4 2023.
• Fourth-quarter 2024 U.S. revenue is expected to be approximately $91 million to $92 million, also representing a 9% to 10% decrease compared to the same period last year.
• Full-year 2024 worldwide revenue is projected to be approximately $408 million to $409 million, a decrease of approximately 4% year-over-year.
• Full-year 2024 U.S. revenue is expected to be approximately $352.5 million to $353.5 million, also reflecting an approximate 4% decrease compared to 2023.
• The company's full-year revenue exceeded previous guidance due to higher-than-anticipated spinal cord stimulation (SCS) device replacement procedures in Q4 2024.
• Cash, cash equivalents, and short-term investments are expected to total approximately $292.5 million as of December 31, 2024, an increase of approximately $15.5 million from September 30, 2024.
• Nevro is continuing to explore strategic options to accelerate growth and diversify its product portfolio.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue declined year-over-year, the company exceeded its own guidance and increased its cash position. The ongoing strategic review adds an element of uncertainty.

Positives

• Full-year 2024 worldwide revenue exceeded the company's previous guidance.
• Cash, cash equivalents, and short-term investments increased by approximately $15.5 million in Q4 2024.
• The company is seeing patient interest and response from its direct-to-consumer (DTC) advertising efforts.
• Nevro's balance sheet remains strong due to working capital management and 2024 restructurings.

Negatives

• Fourth-quarter 2024 worldwide revenue is expected to decrease by 9% to 10% compared to Q4 2023.
• Fourth-quarter 2024 U.S. revenue is expected to decrease by 9% to 10% compared to Q4 2023.
• Full-year 2024 worldwide revenue is expected to decrease by approximately 4% year-over-year.
• Full-year 2024 U.S. revenue is expected to decrease by approximately 4% year-over-year.

Risks

• The company's forward-looking statements are subject to numerous risks and uncertainties, including the ability to successfully commercialize products, manage growth, protect intellectual property, and navigate competition.
• The company's operating results for the period ending December 31, 2024, are not necessarily indicative of the company's operating results for any future periods.
• The company is currently exploring strategic options, which introduces uncertainty regarding its future direction.

Future Outlook

The company expects the benefit from its direct-to-consumer (DTC) advertising to ramp throughout 2025, with a more meaningful impact in the second half of the year. Nevro expects to report its fourth-quarter and full-year 2024 financial results and provide full-year 2025 guidance on its fourth-quarter 2024 earnings call in early March 2025.

Management Comments

• We are pleased that our full-year 2024 worldwide revenue is coming in ahead of our expectations, said Kevin Thornal, Nevro's CEO and president.
• We anticipate that the benefit from our DTC advertising will ramp throughout 2025, with a more meaningful impact in the second half of the year.
• Importantly, our balance sheet remains strong, reflecting our continued focus on working capital management and the benefits from our 2024 restructurings.

Industry Context

Nevro operates in the global medical device industry, specifically focusing on chronic pain treatment through spinal cord stimulation (SCS) and sacroiliac joint fusion. The announcement comes amid ongoing discussions about strategic options, suggesting potential changes in the company's approach to growth and product diversification.

Comparison to Industry Standards

• Companies like Medtronic and Boston Scientific are major players in the spinal cord stimulation market.
• While Nevro's revenue decline contrasts with some growth seen in other areas of the medical device industry, the specific SCS market can be influenced by factors like reimbursement policies and technological advancements.
• The increase in cash reserves is a positive sign, but the company's strategic review suggests it may be seeking ways to better compete with larger, more diversified competitors.

Stakeholder Impact

• Shareholders will be interested in the company's strategic review and its plans to accelerate growth and diversify its product portfolio.
• Employees may be affected by any potential changes resulting from the strategic review.
• Patients may benefit from the company's continued focus on developing comprehensive, life-changing solutions for chronic pain treatment.

Next Steps

• The company expects to report its fourth-quarter and full-year 2024 financial results and provide full-year 2025 guidance on its fourth-quarter 2024 earnings call in early March 2025.
• Nevro will continue to explore strategic options to accelerate its growth, diversify its product portfolio and deliver shareholder value.

Key Dates